-
2
-
-
85015833005
-
-
Version 1.1. Accessed 1 July 2016
-
EUCAST: The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Sone Diameters. Version 1.1. Available at: http://www.eucast.org. Accessed 1 July 2016.
-
Breakpoint Tables for Interpretation of MICs and Sone Diameters
-
-
-
3
-
-
84863730126
-
Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests
-
Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 2012; 33:853-5.
-
(2012)
Infect Control Hosp Epidemiol
, vol.33
, pp. 853-855
-
-
Marchaim, D.1
Sunkara, B.2
Lephart, P.R.3
-
4
-
-
77957866989
-
High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations
-
de Oliveira KR, de Freitas AL, Willers DM, et al. High frequency of beta-lactam susceptibility in CTX-M-type extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae, Escherichia coli and Proteus mirabilis according to the new CLSI recommendations. J Antimicrob Chemother 2010; 65:2481-3.
-
(2010)
J Antimicrob Chemother
, vol.65
, pp. 2481-2483
-
-
de Oliveira, K.R.1
de Freitas, A.L.2
Willers, D.M.3
-
5
-
-
29144493229
-
Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase-and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004)
-
Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase-and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004). Diagn Microbiol Infect Dis 2005; 53:257-64.
-
(2005)
Diagn Microbiol Infect Dis
, vol.53
, pp. 257-264
-
-
Goossens, H.1
Grabein, B.2
-
6
-
-
84873021014
-
Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamaseproducing Enterobacteriaceae: MIC matters
-
Lee NY, Lee CC, Huang WH, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamaseproducing Enterobacteriaceae: MIC matters. Clin Infect Dis 2013; 56:488-95.
-
(2013)
Clin Infect Dis
, vol.56
, pp. 488-495
-
-
Lee, N.Y.1
Lee, C.C.2
Huang, W.H.3
-
7
-
-
84862573595
-
Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-betalactamase-producing Klebsiella pneumoniae and Escherichia coli
-
Chopra T, Marchaim D, Veltman J, et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-betalactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2012; 56:3936-42.
-
(2012)
Antimicrob Agents Chemother
, vol.56
, pp. 3936-3942
-
-
Chopra, T.1
Marchaim, D.2
Veltman, J.3
-
8
-
-
0035003640
-
Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory
-
Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory. J Clin Microbiol 2001; 39:2206-12.
-
(2001)
J Clin Microbiol
, vol.39
, pp. 2206-2212
-
-
Paterson, D.L.1
Ko, W.C.2
Von Gottberg, A.3
-
9
-
-
3042706689
-
Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum betalactamases
-
Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum betalactamases. Clin Infect Dis 2004; 39:31-7.
-
(2004)
Clin Infect Dis
, vol.39
, pp. 31-37
-
-
Paterson, D.L.1
Ko, W.C.2
Von Gottberg, A.3
-
10
-
-
10744230588
-
Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study
-
Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003; 47:3442-7.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 3442-3447
-
-
Zanetti, G.1
Bally, F.2
Greub, G.3
-
11
-
-
33751566651
-
Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge
-
Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extendedspectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43:1407-14.
-
(2006)
Clin Infect Dis
, vol.43
, pp. 1407-1414
-
-
Rodriguez-Bano, J.1
Navarro, M.D.2
Romero, L.3
-
12
-
-
84869484115
-
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis
-
Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:2793-803.
-
(2012)
J Antimicrob Chemother
, vol.67
, pp. 2793-2803
-
-
Vardakas, K.Z.1
Tansarli, G.S.2
Rafailidis, P.I.3
Falagas, M.E.4
-
13
-
-
0141531017
-
Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period
-
Burgess DS, Hall RG II, Lewis JS II, et al. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy 2003; 23:1232-7.
-
(2003)
Pharmacotherapy
, vol.23
, pp. 1232-1237
-
-
Burgess, D.S.1
Hall, R.G.2
Lewis, J.S.3
-
14
-
-
0035189967
-
Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae
-
Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548-54.
-
(2001)
Antimicrob Agents Chemother
, vol.45
, pp. 3548-3554
-
-
Thomson, K.S.1
Moland, E.S.2
-
15
-
-
0035086683
-
In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain
-
Szabo D, Mathe A, Filetoth Z, et al. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2001; 45:1287-91.
-
(2001)
Antimicrob Agents Chemother
, vol.45
, pp. 1287-1291
-
-
Szabo, D.1
Mathe, A.2
Filetoth, Z.3
-
16
-
-
0030956601
-
Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae
-
Thauvin-Eliopoulos C, Tripodi MF, Moellering RC Jr, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41:1053-7.
-
(1997)
Antimicrob Agents Chemother
, vol.41
, pp. 1053-1057
-
-
Thauvin-Eliopoulos, C.1
Tripodi, M.F.2
Moellering, R.C.3
Eliopoulos, G.M.4
-
17
-
-
34547224444
-
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
-
Roos JF, Bulitta J, Lipman J, Kirkpatrick CM. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother 2006; 58:987-93.
-
(2006)
J Antimicrob Chemother
, vol.58
, pp. 987-993
-
-
Roos, J.F.1
Bulitta, J.2
Lipman, J.3
Kirkpatrick, C.M.4
|